icon-folder.gif   Conference Reports for NATAP  
  International HIV and Hepatitis Drug Resistance Workshop
June 8-12, 2010,
Dubrovnik Croatia
Back grey_arrow_rt.gif
Analysis of the HIV-1 gp120 V3 Loop at Screening for Treatment-Experienced Patients in the MOTIVATE Studies With CCR5-Tropic Virologic Failure - poster
  Reported by Jules Levin
International HIV & Hepatitis Virus Drug Resistance Workshop and Curative Strategies June 8-12, 2010Dubrovnik, Croatia
M Lewis1, P Simpson1, B Jubb1, C Craig1, H Valdez2, M Westby11Pfizer Global R&D, Sandwich, Kent, UK; 2Pfizer Inc., New York, NY

Figure 1. Presence of V3 loop mutations 4L or 19S at screening in 83 patients with R5 virus at virologic failure in MOTIVATE 1 and 2

Figure 2. Clonal V3 sequences of 19S variants show additional mutations are associated with phenotypic MVC resistance

Figure 3. Phylogenetic analysis of baseline and on-treatment MVCres(red) and MVCsus(green) clones for patients with MVCresvirologic failure and baseline 19S in the V3 loop shows that the MVCresphenotype is distinct from the majority clones circulating at baseline